PDUFA VII Negotiations Completed, Commitment Letter Ratification Ongoing
The US FDA, HHS and White House, as well as industry groups, now must sign off on the document.
You may also be interested in...
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.
A growing focus on real-world evidence and an expected infusion of user fee funding are among the reasons for the new office branches at US FDA’s biologics center.
Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.